ACN Newswire
TOKYO and CAMBRIDGE, Mass., August 25, 2025 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the anti-amyloid beta(AB) monoclonal antibody “LEQEMBI®” has been launched in Austria on August 25…
Read More
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Yuri Motsinger
22:21
TOKYO and CAMBRIDGE, Mass., August 25, 2025 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the anti-amyloid beta(AB) monoclonal antibody “LEQEMBI®” has been launched in Austria on August 25…
